

— INVESTMENT PLATFORM

The platform for scaling up **healthcare and longevity innovations**

Technology. Capital. International expansion.

MODEL42
INNOVATE. INVEST. EXTEND.

POWERED BY



Model42 transforms medical innovations into scalable health management systems

A UAE-based international platform: an operational portfolio of solutions and an emerging intelligence framework.

Model42 creates a unified framework for diagnostics, medical expertise, data and capital — turning proven solutions into repeatable growth models.

OPERATIONAL PORTFOLIO

TARGET AI FRAMEWORK



01

Person

purpose and context



02

Diagnostics

structured data



03

Expert

expert decision



04

Trajectory

personalization and monitoring

MODEL42 IS NEITHER A CLINIC NOR A COLLECTION OF PRODUCTS

It serves as a framework for selection, rights management, implementation and international commercialization.

The problem is not a lack of innovation, but its fragmentation

A powerful medical solution cannot become a global asset without an implementation framework.



01

Localization

Technology remains within a single clinic, company, or country.



02

Data silos

Diagnosis, treatment and reassessment rarely operate within a single framework.



03

Complex deployment

Each market requires separate regulatory preparation, training and infrastructure.

STRATEGIC GAP

Model42 adds a rights structure, capital and an execution system, transforming innovation into a scalable asset.

One system guiding innovation from selection to international growth

Medical expertise, investment discipline, and global execution.



01

Selection

technology and team



02

Due diligence

clinical validation, market potential and regulatory requirements



03

Capital and rights

ownership and financing structures



04

Implementation

local partners and infrastructure



05

Scale

a repeatable model for new markets

Transforming technology into an investment asset — with a clear ownership structure and a growth roadmap.

The UAE is more than just a base for Model42. It is a catalyst for international growth.

Clinical infrastructure, capital, regulation and global access converge within a single business ecosystem.



01

Clinical base

solution piloting and data collection



02

Capital

investors and strategic partners



03

Regulation

intellectual property, licensing and joint ventures



04

Global access

GCC, Asia, Europe and the CIS



Dubai is shaping an ecosystem for medical and biotech innovation.

Four operating levels. One targeted intelligent framework.

Each level creates its own value; their integration must generate a platform effect.



01 Diagnostics

structured data and risks



02 Therapy

protocols and personalized solutions



03 Education

professional training and unified standards



04 Scaling

partnerships, licensing and joint ventures

TARGET ARCHITECTURE


Model42 target intelligence framework

- Data
- Clinical knowledge
- Rights and economics
- Reassessment

The future intelligent layer must connect data, expert decisions and reassessment.

The portfolio creates a unified framework for health care management

Diagnostics generate data; therapy and personalized treatment plans put the data into action; training solidifies the standard.



Model42 target loop: data → knowledge → expert decision → application → reassessment

Diagnostics become accessible wherever the patient is



Modular point-of-care diagnostic infrastructure.

12M+

tests conducted — based on company data

3,500+

diagnostic systems deployed — based on company data

Model42 diagnostic layer and source of structured medical data.

One diagnostic standard — a unified implementation logic

The infrastructure connects sample collection, analysis, expert interpretation and a compatible data loop.



01

Collection

sample and patient context



02

Analysis

local diagnostic system



03

Interpretation

licensed specialist



04

Integration

further actions and data

Results are interpreted by licensed specialists and used to determine further medical actions.



Value is created not by the product itself, but by the professional protocol

ANF Therapy integrates assessment, personalized selection, application and professional monitoring.

- | | | |
|---|---------------------------|---------------------------|
|  | 01
Assessment | patient condition |
|  | 02
Protocol | individual selection |
|  | 03
Application | ANF products |
|  | 04
Monitoring | evaluation and adjustment |



Application is permitted only by trained and, where required by law, licensed professionals.

ANF scales through a professional network

Training and unified requirements transform the technology into a replicable implementation model.



01

Medical specialist training



02

Partnerships with clinics and health centers



03

Local distribution and support



04

Standardized application protocols



05

Consistent quality standards across every new market



A professional network builds quality, trust and scale

Education reduces the risk of improper implementation

Two programs cover both practical training and the broader context of longevity medicine.

01



ANF ACADEMY

Practical training for specialists in ANF technology application.

METHODOLOGY · TRAINING · PRACTICE

02

LONGEVITY CODE

THE LONGEVITY CODE

International educational program in functional, preventive, and regenerative medicine.

KNOWLEDGE · PROTOCOLS · INTERNATIONAL EXCHANGE

The proposed launch model based on a local license

Model42 provides the operational model and support within the scope of contractual rights, while the partner is responsible for regulated activities.

01

JOINT VENTURE

Model42 and a local partner launch a licensed pharmacy operation in the selected market.

02


PERMITTED PARTNERSHIP MODEL

Licensing or franchising is implemented only where legally permissible and approved by the regulator.



The future analytical layer is intended to integrate diagnostics, expert decision and reassessment.

The target framework is viewed as a support tool, not a replacement for a licensed professional.



Medical data may only be processed upon receipt of the required consents and in compliance with applicable legislation.

The commercial model integrates three potential levels of value creation

A successful launch in a new market can expand current operations, contractual rights, and the value of portfolio assets.



01

OPERATING REVENUE

Diagnostic systems and services · professional application · training · local pharmacy structures



02

PLATFORM REVENUE

Licensing rights · viable franchise models · joint ventures



03

PORTFOLIO VALUE

Increase in value of verified stakes, rights, intellectual property and infrastructure

Each revenue stream and asset is recognized only upon the establishment of the corresponding contractual and corporate rights.

The choice of entry model depends on the level of control, capital requirements and regulatory complexity

The legal and operational structure must align with the product and the jurisdiction.

ENTRY MODEL	CONTROL	CAPITAL	SPEED
01 DIRECT PRESENCE	Maximum control	High	Medium
02 JOINT VENTURE	Shared control	Shared	Medium
03 FRANCHISING	Contractual standards	Partner	Higher*
04 LICENSING / DISTRIBUTION	Limited	Partner	High

* Only if permitted by the applicable jurisdiction.

Priority markets are evaluated progressively, not simultaneously

The UAE acts as a base for gradual international expansion.

-  **01 THE UAE**
base market and international hub
-  **02 GULF COOPERATION COUNCIL COUNTRIES (GCC)**
regional growth wave
-  **03 CIS**
Russia, Kazakhstan, Uzbekistan, and neighboring markets
-  **04 SELECTED INTERNATIONAL MARKETS**
select markets in Asia, Europe, and Africa



A single successfully launched market creates an operational model for the next wave.

The status of assets and infrastructure is presented separately

This prevents the conflation of existing solutions, contractual relationships and future plans.

ACTIVE PORTFOLIO AND PARTNERSHIP SOLUTIONS

- 01** Clinics on Cloud
- 02** ANF Therapy
- 03** ANF Academy
- 04** The Longevity Code
- 05** Energy Max Group (incl. Maxilin flagship technology)
- 06** New medical and biotech assets

MODEL42 INFRASTRUCTURE UNDER DEVELOPMENT

- 01** Model42 Compounding Pharmacy
- 02** International joint ventures
- 03** Unified digital infrastructure

The status, contractual rights and actual results of each workstream are documented.

The target model accumulates rights and infrastructure that preserve long-term value

An asset is recognized only upon the availability of supporting corporate, contractual and licensing documentation.



01 EQUITY INTERESTS

participation in the value growth of verified portfolio assets, including a 25% stake in Energy Max Group

EXISTING / ACQUIRED



02 COMMERCIAL RIGHTS

development of solutions in agreed territories

CONTRACT-BASED ONLY



03 OPERATIONAL INFRASTRUCTURE

training, partnerships, licensing and launch

UNDER DEVELOPMENT



04 INTELLECTUAL PROPERTY

digital tools, expertise and scaling model

EXISTING / UNDER DEVELOPMENT

Value is created not only by product sales but by the entire market access system.

Enlightened Minds Investments provides the framework, capital access and execution support

Model42 is a specialized health and longevity ecosystem within the EMI investment platform.

-  **01 CORPORATE ARCHITECTURE**
ownership and partnership structures
-  **02 CAPITAL ACCESS**
investors and strategic relationships
-  **03 NEW MARKETS**
international joint ventures and partners
-  **04 DEALS AND EXECUTION**
commercialization and scaling; case: cross-ownership with Energy Max Group



EMI transforms medical opportunities into structured investment platforms.

NAZR Ventures expands international reach for Model42

Partnership accelerates deal sourcing, capital access and international commercialization.



NAZR VENTURES

Healthcare · Life Sciences · Longevity · AI



01

International investors and family investment offices



02

Medical and institutional organizations



03

Sourcing and selection of new technologies and companies



04

Market entry: North America, Europe, Asia and the Middle East

STRATEGIC INTERNATIONAL PARTNER

Strategic partner & portfolio company

Energy Max Group expands the Model42 product line



FLAGSHIP PRODUCT

Maxilin



01

Global operational infrastructure with a presence in 30+ countries.



02

Development and manufacturing of premium biotechnological products (flagship — Maxilin).



03

Strategic cross-ownership (25% stake) for mutual integration and scaling.



04

Implementation of products into Model42's corporate B2B/B2C channels exclusive of the MLM model.

Selected clients and partners of Clinics On Cloud.



Executive Management

Strategic management, medical expertise and international development.



EXECUTIVE CHAIR

Timur Kudratov

Strategic Planning, Capital & Ecosystem Architecture



VICE CHAIR

Dr. Raees Tonse, MD, MBA

Oncology, Precision Medicine & International Partnerships



MANAGING PARTNER OF MODEL42 FOR MEDICAL PRODUCTS AND INNOVATIONS

Dr. Aida Gadjeva

Managing Partner for Medical Products and Innovation at Model42



INVESTOR RELATIONS LEADER AT MODEL42

Leyla Didigova

Head of Investor Relations at Model42

International Advisory Board

Institutional strategy, investment management, global development & sustainability.



Ali Qassim Al-Asiri

Strategy & Public Sector Transformation



Mohammed Alkaff Al-Hashmi

Finance, Technology & Strategic Investments



Carlo Almeida

Latin America: Business & Partnership Development



Dr. Samiullah (Samuel) Khan

ESG, Net Zero & Sustainable Transformation

International Advisory Board

Healthcare, financing, international commercialization, and market development.



Armands Murnieks

Nutraceuticals, International
Commercialization and Partner Network



Dr. Dennis Sebastian

Health Insurance and Healthcare
Financing



Chad Chavanda

Africa: Market Development and
International Trade

Model42 is looking for partners capable of putting solutions into practice

The key value of a partner is a specific capability: a license, infrastructure, an audience, capital or a scientific base.



01 CLINICS AND MEDICAL CENTERS

diagnostics and therapeutic solutions



02 PHYSICIANS AND SPECIALISTS

training and professional networking



03 DISTRIBUTORS AND NETWORK OWNERS

commercialization in agreed-upon territories



04 UNIVERSITIES AND EDUCATIONAL ORGANIZATIONS

programs and research initiatives (subject to approvals)



05 ENTREPRENEURS AND INSTITUTIONAL PARTNERS

joint ventures and new infrastructure

A partner must add not status, but the capability to launch

Five partnership formats cover various stages of the patient journey

The choice depends on market objectives, licensing requirements and partner resources.



01

Clinics on Cloud

Diagnostic infrastructure for clinics, corporations and remote sites.



02

ANF Therapy

Professional network, training and implementation of application standards.



03

Model42 Compounding

Joint venture or legally compliant partnership model.



04

Education & science

Professional programs and institutional initiatives.



05


Energy Max / Maxilin

Implementation of advanced probiotic protocols into clinical practice through direct B2B contracts.

The partnership format follows the market objective — not the other way around.

Collaboration begins by defining the market, the lead executive and the success criteria

Six stages transform interest into a controlled launch.



Every launch must have an owner, a licensing framework and a measurable outcome.

Important Information

This document is intended solely for preliminary review and discussion purposes.



01

DOCUMENT STATUS

This presentation is for informational and marketing purposes only. It does not constitute a public offer, investment recommendation or medical or legal advice.



02

PLANS AND FORECASTS

Information regarding plans, markets, potential revenues and asset values contains forward-looking statements and does not guarantee future results. The recipient is expected to conduct their own due diligence.



03

MEDICAL AND PHARMACEUTICAL ACTIVITIES

Model42 does not independently provide medical or pharmaceutical services. Such services may only be provided by separate licensed entities and professionals in accordance with the laws of the relevant jurisdiction.



04

TECHNOLOGY, DATA AND AI

The description of technologies does not imply confirmation of efficacy, safety, or regulatory approval in any given market. Data and AI tools may only be used subject to obtaining necessary consents and in compliance with applicable laws.

Any cooperation is governed exclusively by signed agreements and applicable law.



Shaping the future of health and longevity together

ICTS Training Center · 25A St, Al Quoz Industrial Area 3 · Dubai, UAE

info@model42.ae

model42.ae

POWERED BY

